In line with its stated strategy for Sequent 2.0, this acquisition marks Alivira's foray into Brazil's pet market, fastest growing segment in Brazil, and 4th largest pet market in the world. The acquisition will be made through Evance Saude Animal Health (Evance), subsidiary of Alivira Brazil, for a cash consideration of BRL 27 Million, and is expected to close in Q4 FY22.

Nourrie specializes in development and commercialization of nutraceuticals and therapeutic products, with a portfolio of 23 commercialized products for pet and swine, and a near-term pipeline of 17 products. The business is well established with integrated R&D and manufacturing setup, complementary to Alivira's existing local capabilities. The Company also manufactures Transuin, a Ractopamine based product for swine, a key product in Alivira Brazil's portfolio. This transaction also strengthens the global Alivira team with the induction of Dr. Geraldo José Arantes, the erstwhile R&D head of Elanco for Latam region and shall participate in the global R&D program of Alivira.

Since its acquisition in 2016, Alivira Brazil (Evance) has emerged to be amongst Top 10 ranked animal health players in Brazil, having grown significantly at a CAGR of 57% over the last 5 years, achieving revenues of ~BRL 114 Mn TTM Sep 2021. It has established strong presence in livestock segment with a portfolio of 40+ commercialized products.

This transaction further builds on Alivira's strong track record of global acquisitions, having successfully acquired and integrated 9 companies across Europe, Latam and India in the last 7 years.